NCT04579380 2025-12-19Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 AlterationsSeagen Inc.Phase 2 Active not recruiting217 enrolled 19 charts
NCT02091141 2024-07-23My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid TumorsGenentech, Inc.Phase 2 Completed673 enrolled 22 charts
NCT03319459 2021-11-22FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid TumorsFate TherapeuticsPhase 1 Completed44 enrolled
NCT04464967 2021-05-12Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR CancersNKGen Biotech, Inc.Phase 1/2 Withdrawn
NCT02006667 2015-02-11A Study of Herceptin (Trastuzumab) Combination Therapy in Patients With Metastatic Urothelial CancerHoffmann-La RochePhase 2 Completed13 enrolled 12 charts
NCT02013765 2014-09-25A Study of Herceptin (Trastuzumab) Monotherapy in Patients With Metastatic Urothelial CancerHoffmann-La RochePhase 2 Terminated5 enrolled 12 charts